High-risk group’s priority for latest adapted Covid-19 vaccines: ECDC
Priority should be given to those in high-risk groups and healthcare workers, according to the European Centre for Disease Prevention and Control (ECDC),
when the most recent adapted Covid-19 vaccines are introduced across the continent this summer.
The European Centre for Disease Prevention and Control stressed the importance of taking these measures to avoid overwhelming healthcare systems.
According to the European Medicines Agency, the vaccines Comirnaty Original/Omicron BA.1 and Spikevax Bivalent Original/Omicron BA.1 have been approved for use in the European Union as of late, as reported by the Xinhua news agency.
According to the report, both are superior to currently available vaccines in terms of protecting against the Omicron BA.1 variant and other lineages.
According to Andrea Ammon, director of the European Centre for Disease Prevention and Control (ECDC), “with the newly authorised adapted Cocid-19 vaccines,
member states will now have more options to roll out autumn/winter Covid-19 immunisation campaigns aimed at protecting the most vulnerable groups, and boost their immunity against the most recent emerging variants.”
Individuals aged 12 and up are now able to use the new vaccines as booster doses, per regulatory approval.
However, ECDC emphasised that priority should be given to those over the age of 60, those with preexisting medical conditions, pregnant women, and residents and employees of long-term care facilities.
Meanwhile, it’s crucial to give extra emphasis to providing booster shots to healthcare workers.
The European Centre for Disease Prevention and Control (ECDC) warns that “timely vaccination and deployment of boosters ahead of a potential autumn and winter surge of Covid-19 cases is essential” for protecting people and
preventing health systems from becoming overwhelmed. According to Ammon, the vaccines currently in use are still crucial.
She explained that the original vaccines are still necessary to boost vaccination coverage because the newer ones are only approved for use as booster doses.